^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Vigil (gemogenovatucel-T)

i
Other names: Bi-shRNAfurin, bi-shRNAfurin/GMCSF augmented autologous tumor cell vaccine, IND14205, TGFbeta2 antisense + rhGMCSF vaccine, TAG vaccine, bi-shRNAfurin/GMCSF autologous tumor cell vaccine
Associations
Company:
Gradalis
Drug class:
GM-CSF agonist, TGF-β1 inhibitor, TGF-β2 inhibitor
Associations
3ms
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. (PubMed, Future Oncol)
Transfected plasmid components contain an expressive human GMCSF DNA segment to enhance anticancer immune functional response and a second component expressing bi-shRNAfurin which reduces TGFβ isomers (TGFβ1 and TGFβ2) thereby reducing cancer inhibition of the targeted immune response. Results generated to date justify advancement to confirmatory clinical trials supporting product regulatory approval.
Review • Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme) • TGFB2 (Transforming Growth Factor Beta 2)
|
Vigil (gemogenovatucel-T)
11ms
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response. (PubMed, Cancers (Basel))
Vigil is an autologous cellular immunotherapy which is designed to carry the full set of personal clonal neoantigens. Phase 2b results demonstrate a durable recurrence-free survival (RFS) and overall survival (OS) advantage for Vigil in a subset ovarian cancer population with an HRP cancer profile.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
Vigil (gemogenovatucel-T)
1year
Advances in Targeted Therapy for the Treatment of Cervical Cancer. (PubMed, J Clin Med)
We have consolidated information regarding the role of the immune system in both disease progression and disease clearance with the aid of targeted therapies and immunotherapeutic agents. Additionally, we have characterized the treatment modalities currently indicated as the standard of care-such as bevacizumab and the immune CPIs-and those recently approved or in development, including Tivdak, Vigil, and chimeric antigen receptor (CAR) T-cells.
Review • Journal
|
Avastin (bevacizumab) • Tivdak (tisotumab vedotin-tftv) • Vigil (gemogenovatucel-T)
over1year
VITAL: A Trial of Vigil for Participants With Ovarian Cancer (clinicaltrials.gov)
P2, N=92, Active, not recruiting, Gradalis, Inc. | Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date • Surgery • Tumor cell
|
Vigil (gemogenovatucel-T)
over1year
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. (PubMed, Commun Med (Lond))
NSA should be considered for application to investigational targeted therapies in order to identify populations most likely to benefit from treatment, in preparation for efficacy conclusive trials.
Journal • IO biomarker
|
CSF2 (Colony stimulating factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • TGFB2 (Transforming Growth Factor Beta 2)
|
PD-1 expression • CSF2 expression • ENTPD1 expression
|
Vigil (gemogenovatucel-T)
over1year
Journal
|
EWSR1 (EWS RNA Binding Protein 1) • CSF2 (Colony stimulating factor 2) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme)
|
temozolomide • Vigil (gemogenovatucel-T)
over1year
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (clinicaltrials.gov)
P2, N=25, Completed, Gradalis, Inc. | Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> May 2022
Trial completion • Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • Vigil (gemogenovatucel-T)
over1year
Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing (AACR 2023)
Gemogenovatucel-T is a cellular immunotherapy manufactured from harvested tumor tissue transfected with a plasmid which encodes granulocyte macrophage colony stimulating factor (GM-CSF) and a short harpin RNA which specifically reduces the expression of furin and downstream targets TGF-β1, and TGF- β2...The entire process starting with blood DNA extraction and ending with report generation can be completed in about 3.5 days. The results show that a comprehensive oncology-focused sequencing panel can be an effective tool for focused gene-specific variant analysis.
Clinical • BRCA Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CSF2 (Colony stimulating factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme)
|
BRCA2 mutation • BRCA1 mutation • BRCA wild-type • BRCA mutation
|
Vigil (gemogenovatucel-T)
2years
Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Oncol)
At the same time, treatment with the Gemogenovatucel-T (Vigil) is safer than other treatment modalities and does not have any toxic effects. https://www.crd.york.ac.uk/prospero/, identifier (CRD42022300367).
Retrospective data • Review
|
BRCA (Breast cancer early onset)
|
BRCA wild-type
|
Vigil (gemogenovatucel-T)
2years
ENTPD1 as predictive marker of treatment response to Gemogenovatucel-T (Vigil) in newly diagnosed ovarian cancer (SITC 2022)
ENTPD1 high may predict a more sensitive OC population to Vigil. Trial Registration NCT02346747
BRCA Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CSF2 (Colony stimulating factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • TGFB2 (Transforming Growth Factor Beta 2)
|
BRCA wild-type • PD-1 expression • CSF2 expression
|
Vigil (gemogenovatucel-T)
2years
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. (PubMed, Commun Med (Lond))
Using the NanoString Statistical Algorithm (NSA), we identify high expression of ENTPD1/CD39 (which functions as the rate-limiting step in the production of the immune suppressor adenosine from ATP to ADP) as a presumptive predictor of response to Vigil versus placebo regardless of HRP status on the basis of relapse free survival (median not achieved vs 8.1 months, p = 0.00007) and overall survival (median not achieved vs 41.4 months, p = 0.013) extension. NSA should be considered for application to investigational targeted therapies in order to identify populations most likely to benefit from treatment, in preparation for efficacy conclusive trials.
Journal • IO biomarker
|
CSF2 (Colony stimulating factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • TGFB2 (Transforming Growth Factor Beta 2)
|
PD-1 expression • CSF2 expression
|
Vigil (gemogenovatucel-T)
over2years
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. (PubMed, Clin Med Insights Oncol)
Further evidence of clinical benefit and safety has been demonstrated in combination with atezolizumab. Prolonged progression-free survival was improved in patients with PD-L1+ tumors (n = 8, hazard ratio = 0.304, 95% confidence interval, 0.0593-1.56, 1-sided P = .04715) compared with those with PD-L1- tumors. Vigil plus durvalumab was well tolerated and showed promising clinical activity in advanced BRCA-wt TNBC and stage III-IV recurrent/refractory OC patients.
Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
BRCA (Breast cancer early onset) • TGFB1 (Transforming Growth Factor Beta 1)
|
BRCA wild-type
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Vigil (gemogenovatucel-T)
almost3years
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer (clinicaltrials.gov)
P2, N=44, Active, not recruiting, Gradalis, Inc. | Trial completion date: Dec 2021 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jun 2023
Trial completion date • Trial primary completion date
|
CSF2 (Colony stimulating factor 2)
|
Vigil (gemogenovatucel-T)
almost3years
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. (PubMed, Gynecol Oncol)
In conclusion, results suggest durable activity of Vigil on RFS and OS and support further evaluation of Vigil in HRP ovarian cancer.
Clinical • Journal
|
BRCA (Breast cancer early onset)
|
BRCA wild-type
|
Vigil (gemogenovatucel-T)
almost3years
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. (PubMed, Cancer Gene Ther)
Results suggest a subset of ovarian cancer patients with enhanced susceptibility to Vigil immunotherapy. The hypothesis-generating data presented invites a validation study of Vigil in target identified populations, and supports clinical consideration of STRING-generated network application to biomarker characterization with other cancer patients targeted with Vigil.
Clinical • Journal • Tumor Mutational Burden • BRCA Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
|
Vigil (gemogenovatucel-T)
over3years
[VIRTUAL] Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial. (ASCO 2021)
Vigil immunotherapy as frontline maintenance in Stage III/IV ovarian cancer is well tolerated and showed clinical benefit in both BRCA-wt and HRP molecular profile patients . Results suggest a unique molecular network that enhances sensitivity to Vigil therapy.
P2b data • Clinical • BRCA Biomarker • IO biomarker
|
HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • CSF2 (Colony stimulating factor 2) • TGFB1 (Transforming Growth Factor Beta 1)
|
HRD
|
Myriad myChoice® CDx
|
Vigil (gemogenovatucel-T)
over3years
Journal • Clinical
|
BRCA (Breast cancer early onset)
|
BRCA wild-type
|
Myriad myChoice® CDx
|
Vigil (gemogenovatucel-T)
almost4years
Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119) (clinicaltrials.gov)
P2, N=25, Active, not recruiting, Gradalis, Inc. | Trial completion date: Feb 2021 --> Sep 2022 | Trial primary completion date: Jan 2020 --> Jan 2021
Clinical • Trial completion date • Trial primary completion date
|
TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Vigil (gemogenovatucel-T)
almost4years
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. (PubMed, Lancet Oncol)
Front-line use of gemogenovatucel-T immunotherapy as maintenance was well tolerated but the primary endpoint was not met. Further investigation of gemogenovatucel-T in patients stratified by BRCA mutation status is warranted.
Clinical • P2b data • Journal • BRCA Biomarker • IO biomarker
|
BRCA (Breast cancer early onset) • TGFB1 (Transforming Growth Factor Beta 1)
|
BRCA mutation
|
carboplatin • paclitaxel • Vigil (gemogenovatucel-T)
almost4years
Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer (clinicaltrials.gov)
P2, N=44, Active, not recruiting, Gradalis, Inc. | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date
|
CSF2 (Colony stimulating factor 2)
|
Vigil (gemogenovatucel-T)
4years
[VIRTUAL] Randomized Double-Blind Placebo Controlled Trial of Frontline Maintenance Vigil Immunotherapy (VITAL study) in Stage III/IV Ovarian Cancer: Efficacy Assessment in BRCA1/2-wt Patients (IGCS 2020)
Vigil immunotherapy as 1L maintenance in Stage III/IV ovarian cancer is well tolerated and showed significant RFS clinical benefit, particularly in BRCA1/2-wt disease.
Clinical • BRCA Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CSF2 (Colony stimulating factor 2)
|
HRD
|
Vigil (gemogenovatucel-T)
over4years
[VIRTUAL] A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients. (ASCO 2020)
The combination of Vigil immunotherapy and checkpoint inhibitor atezolizumab in recurrent OvC demonstrated safety and suggest a lower toxicity profile and a significant OS advantage in recurrent BRCA1/2-wt OvC patients treated with Vigil first followed by the combination of Vigil and Atezolizumab. Research Funding: None
Clinical • P1 data • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CSF2 (Colony stimulating factor 2)
|
Tecentriq (atezolizumab) • Vigil (gemogenovatucel-T)
over4years
[VIRTUAL] Randomized double-blind placebo controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients (SGO-I 2020)
Front-line use of vigil immunotherapy as maintenance in stage III–IV ovarian cancer is well tolerated and showed trend in RFS clinical benefit. Specifically, BRCA1 and BRCA2wt disease showed statistically significant benefit.
Clinical • BRCA Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CSF2 (Colony stimulating factor 2)
|
Vigil (gemogenovatucel-T)
over4years
[VIRTUAL] Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients. (ASCO 2020)
Vigil immunotherapy as frontline maintenance in Stage III/IV ovarian cancer is well tolerated and showed RFS clinical benefit, particularly in BRCA1/2-wt disease. Research Funding: None
Clinical • BRCA Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CSF2 (Colony stimulating factor 2)
|
Vigil (gemogenovatucel-T)
almost5years
Randomized double-blind placebo controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients (SGO 2020)
Front-line use of vigil immunotherapy as maintenance in stage III–IV ovarian cancer is well tolerated and showed trend in RFS clinical benefit. Specifically, BRCA1 and BRCA2wt disease showed statistically significant benefit.
Clinical • Late-breaking abstract • BRCA Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CSF2 (Colony stimulating factor 2)
|
Vigil (gemogenovatucel-T)